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Abstract
Endocrine regulation in the brain is important for body growth and metabolism both in human and domestic
animals. Growth hormone (GH) has been recognized as a primary regulator that plays an important role in
determining body composition to maintain beneficial ratio between skeletal muscle and fat. The main targets
of GH actions are liver, muscle, and bone where this action is partially mediated through an increase in
insulin-like growth factor-_ (IGF-_). A role for GH in the brain is more critically approached because its
pulsatile secretion is regulated by dual system of hypothalamic control: a positive/negative feedback loop.
Growth hormonereleasing hormone (GHRH) is released from arcuate neurons in the hypothalamus and
transported through the portal blood vessels into the pituitary gland, where it stimulates GH release from
somatotrophs (GH-secreting cells in the pituitary gland). Negative feedback is mediated by the release of
somatostatin (SS) from hypothalamic neurons that act to inhibit GH release. A third endocrine pathway
controlling GH secretion has been led by discovery of the GH secretagogues (GHSs); growth hormone-
releasing peptides (GHRPs) and their pharmacological nonpeptidyl analogs that have a direct effect on in
vitro pituitary GH release in both animal and human somatotrophs. GHSs synergize with GHRH and
functionally antagonize SS acting on the hypothalamus for GH secretion. Alterations in GH pulsatility are
seen in a variety of physiological and pathological circumstances, including puberty, aging, estrous cycle,
obesity, starvation, and growth delay. Disconnection of hypothalamic-pituitary stalk results in loss of normal
GH pulsatility and suggests that pulsatility is regulated by changes in GHRH, SS, and a natural ligand for GHS
receptor. GHSs administrated alone or in combination with GHRH are the most potent and reproducible GH
releasers, and useful tools for the diagnosis of GH deficiency when tested in a variety of pathological
condition in patients and across many species. Therefore, GHSs present a factor for extending the
understanding of GH secretion, as well as a unique therapeutic opportunity. Neuropeptide Y (NPY) has been
well known mediators not only in GH-secreting mechanism by GHSs but also in food intake -relating network
in hypothalamic neurons. Previous studies suggest that NPY has negative feedback effect of GH release and
stimulatory action in the regulation of appetite having reciprocal relation with hypothalamic hormone such as
GHRH, SS, GHS and leptin. In addition to stimulating body growth, alterations in nutritional status such as
obesity or food deprivation significantly influence GH secretion. Leptin secreted by adipocytes that regulates
food intake and energy expenditure has recently been shown to play a stimulatory role on GH secretion.
Leptin induced GH secretion is suppressed by NPY, so it is possible that NPY mediates leptin action in the
hypothalamus. Another candidate for GH regulation in the hypothalamic area is ghrelin, a GH-releasing
acylated peptide as an endogenous bioactive ligand for the GHS receptor. Ghrelin produced by stomach,
intestine, placenta, pituitary, and possibly in the hypothalamus is a recently discovered hormone that plays a
critical role in the maintenance of energy homeostasis as well as the stimulation of GH release. GH secretion
results from a complex series of interactions that occur both in peripheral tissue and in the central nervous
system (CNS). The regulation of growth by elements of the GH axis is a complex process that we have only
begun to understand. Further evaluation of physiology and genes involved in the production, secretion, and
actions of GH will enhance our understanding of the role and central mechanisms of endocrine regulation
affecting growth
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Summary and Implications
Endocrine regulation in the brain is important for
body growth and metabolism both in human and domestic
animals.  Growth hormone (GH) has been recognized as a
primary regulator that plays an important role in
determining body composition to maintain beneficial ratio
between skeletal muscle and fat.  The main targets of GH
actions are liver, muscle, and bone where this action is
partially mediated through an increase in insulin-like
growth factor-_ (IGF-_).  A role for GH in the brain is
more critically approached because its pulsatile secretion
is regulated by dual system of hypothalamic control:  a
positive/negative feedback loop. Growth hormone-
releasing hormone (GHRH) is released from arcuate
neurons in the hypothalamus and transported through the
portal blood vessels into the pituitary gland, where it
stimulates GH release from somatotrophs (GH-secreting
cells in the pituitary gland).  Negative feedback is
mediated by the release of somatostatin (SS) from
hypothalamic neurons that act to inhibit GH release.
A third endocrine pathway controlling GH secretion
has been led by discovery of the GH secretagogues
(GHSs); growth hormone-releasing peptides (GHRPs)
and their pharmacological nonpeptidyl analogs that have a
direct effect on in vitro pituitary GH release in both
animal and human somatotrophs.  GHSs synergize with
GHRH and functionally antagonize SS acting on the
hypothalamus for GH secretion. Alterations in GH
pulsatility are seen in a variety of physiological and
pathological circumstances, including puberty, aging,
estrous cycle, obesity, starvation, and growth delay.
Disconnection of hypothalamic-pituitary stalk results in
loss of normal GH pulsatility and suggests that pulsatility
is regulated by changes in GHRH, SS, and a natural
ligand for GHS receptor. GHSs administrated alone or in
combination with GHRH are the most potent and
reproducible GH releasers, and useful tools for the
diagnosis of GH deficiency when tested in a variety of
pathological condition in patients and across many
species. Therefore, GHSs present a factor for extending
the understanding of GH secretion, as well as a unique
therapeutic opportunity.
Neuropeptide Y (NPY) has been well known
mediators not only in GH-secreting mechanism by GHSs
but also in food intake -relating network in hypothalamic
neurons. Previous studies suggest that NPY has negative
feedback effect of GH release and stimulatory action in
the regulation of appetite having reciprocal relation with
hypothalamic hormone such as GHRH, SS, GHS and leptin.
In addition to stimulating body growth, alterations in
nutritional status such as obesity or food deprivation
significantly influence GH secretion.  Leptin secreted by
adipocytes that regulates food intake and energy expenditure
has recently been shown to play a stimulatory role on GH
secretion.  Leptin induced GH secretion is suppressed by
NPY, so it is possible that NPY mediates leptin action in the
hypothalamus.
Another candidate for GH regulation in the hypothalamic
area is ghrelin, a GH-releasing acylated peptide as an
endogenous bioactive ligand for the GHS receptor.  Ghrelin
produced by stomach, intestine, placenta, pituitary, and
possibly in the hypothalamus is a recently discovered hormone
that plays a critical role in the maintenance of energy
homeostasis as well as the stimulation of GH release.
GH secretion results from a complex series of interactions
that occur both in peripheral tissue and in the central nervous
system (CNS).  The regulation of growth by elements of the
GH axis is a complex process that we have only begun to
understand.  Further evaluation of physiology and genes
involved in the production, secretion, and actions of GH will
enhance our understanding of the role and central mechanisms
of endocrine regulation affecting growth.
Review
      Growth hormone (GH).  Growth hormone has growth-
promoting effects and metabolic actions that are important in
many species and acts directly or indirectly on virtually every
tissue in the body. These biological events of GH are initiated
by hormone binding to its cell surface receptor and trigger
gene expression for long term changes that are responsible for
the stimulation of growth. Insulin-like growth factor I (IGF-I),
a highly conserved to amino acid is one of the key targets for
GH. GH has direct effects in many tissues coordinating with
locally generated/circulating IGF-I to enhance growth in
animals. It is well known that GH treatment induces IGF-I and
stimulates IGF-I expression in the liver and other tissues.
GH receptor (GHR) is expressed in many tissues,
including liver, heart, fat, testis, skeletal muscle, intestine,
kidney, pancreas, and brain. Especially brain is considered as
an important target tissue for GH supposed by increasing
direct evidence. High-resolution autoradiography and
immunocytochemistry and in situ hybridization has been used
to confirm GHR expression in the CNS-hypothalamus and
hippocampus in rodents and human. Within the hypothalamus,
GHRs are involved in a short feedback regulating GH
secretion:  high GH expression induces periventricular nucleus
(PVN) somatostatin (SS) neurons to increase SS expression
and arcuate nucleus (ARC) to inhibit GHRH expression,
consistent with GH feedback. Decrease of GHR expression in
hypophysecromy or in dwarf rat, which has GH deficiency,
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shows that central GHR expression is also sensitive to
regulation by GH.
In most species, GH is secreted in a pulsatility pattern
and is regulated by tightly controlled feedback pathways.
Two hypothalamic hormones highly involved in the
feedback loop are GHRH and SS. This episodic pulsatility
reflects a balanced alteration in two neuroendocrine
systems regulating GH release by a positive/negative
feedback loop.
      GHRH and SS.  GHRH is a peptide hormone
synthesized and released from the hypothalamic arcuate
nucleus (ARC) that stimulates GH secretion from
pituitary somatotroph cells (GH secreting cells). The
pituitary cell membrane has specific, high-affinity binding
sites for GHRH. Binding GHRH to its receptor stimulates
adenylate cyclase, resulting increased adenosine 3'5'-
cyclic monophosphate (cAMP) production, and indicating
that the Gs protein is an intermediate in GHRH action.
Because cAMP is an important second messenger for
GHRH signaling, GHRH and cAMP stimulate pituitary
GH secretion, facilitate GH gene expression, and increase
the proliferation of cultured pituitary somatotroph cells.
SS or somatotrophin-releasing inhibiting factor
(SRIF) is a 14 amino acid-containing peptide hormone
primarily expressed in the hypothalamus. A major
physiological function of SRIF is to inhibit GH release
and maintain the pulsatile secretion of GH. SRIF inhibits
GH release by activating the receptor subtype sstr2 to
inhibit Ca2+ conductance and Ca2+ influx in somatotrophs.
The GH feedback loop by GHRH and SRIF on
pulsatile GH release is maintained with time. GHRH
expression is increased in the case of GH deficiency,
whereas GH treatment reverses changes. Conversely,
SRIF expression in the hypothalamus is reduced after
hypophysectomy, whereas excess GH stimulates
hypothalamic SRIF synthesis and release. The main
physiological role of GH feedback on GHRH is to
regulate the GH reserve for a much longer time. Although
local generation of IGF-I in response to GH secretion in
the CNS is considered to be important, changes in GHRH
and SRIF are readily observed with GH, but not with
IGF-I alone, which implicates sites of direct feedback for
GH and not secondary to peripheral IGF-I generation.
      GHS.  Pulsatile GH secretion from the pituitary
somatotrophs was thought to be regulated by episodic
changes only in two hypothalamic hormone, GHRH and
SRIF. However, the discovery of synthetic GHRP by
Bowers and coworkers and several nonpeptidyl GHSs,
including L-692,429, L-692,585, and MK-0677 that also
act to enhance GH release  has brought an emerging
perspective in the endogenous regulation of GH secretion.
GHRP-6 stimulates pulsatile GH release through the
activation of a receptor distinct from the SRIF and GHRH
receptor, which belongs of the family of seven
transmembrane receptor coupled to GTP binding protein
to up-down-regulate cAMP level controlling GH secretion.
Peptidyl and nonpeptidyl GHS receptors cloned in the anterior
pituitary and hypothalamus are activated by a mediator, a
phosphoinositol-protein kinase C intracellular pathway that
induces intracellular Ca2+ release and depolarization, leading
to exocytosis of GH-containing secretory vesicles in the
pituitary gland.
GHSs may have dual action to stimulate endogenous
GHRH release and suppress endogenous somatostatin release,
which implies GHSs require the presence of a functional
hypothalamus. In situ hybridization studies in monkey and rat
brains show that GHS-R is expressed in arcuate neurons,
suggesting that GHS-R ligand stimulates these neurons
directly as a GHRH releaser that induces GH secretion from
the somatotrophs. GHS and GHRH have a synergistic effect
and even very low GHS doses potentiate the GHRH-induced
GH rise in human and animals. Hypothalamopituitary
disconnection (functional stalk section) fails to respond to
GHSs for optimal GH release. Experiment in hypothalamic
stalk-sectioned pigs showed that GHS-induced GH release is
blocked and synergistic action of GHRH and GHS is absent.
Electophysiological studies in vivo show that neurosecretory
neurons in the hypothalamic arcuate nucleus are excited by
GHSs and are inhibited during electrical stimulation of
periventricular nucleus. Also, after intravenous injection of
somatostatin, secretagogue-responsive cells are inhibited.
Thus, it would appear that a subpopulation of the arcuate cells
activated by GHSs is inhibited by central somatostatin action.
These important studies link the action of GHS-R ligands with
two endogenous regulators of GH release, GHRH and
somatostatin, which are important to generate the rhythm of
GH pulsatility.
Interestingly, studies in animals have suggested that
GHSs may have widespread effect in the brain and interfere
with secretion of neuropeptide Y and dopamine, which leads
to up-regulation of adrenocorticotropin (ACTH), cortisol, and
prolactin secretion. For example, the nonpeptide GHRP analog
L-692,429 powerfully stimulated prolactin secretion from
pituitary somatomammotrope cells (both GH and PRL
secreting cells). This study implies that GHS might include
mastopathy, galactorrheas, and/or a loss of libido. A most
important reason prompting GHS research is its benefit of oral
administration to release GH. Therefore, it would be useful in
clinical practice for diagnostic and therapeutic purpose as well
as potential in regulating GH secretion in farm animals.
      Neuropeptide Y (NPY).  NPY has been implicated as a
regulator in the control of appetite, body weight gain, and
obesity, and is also involved in central mechanism of GH
release. NPY expression is GH sensitive and may be the
primary target for GH feedback in the ARC. Previous studies
showed that ARC NPY mRNA is reduced in GH-deficient
dwarf rats and this deficiency is corrected by GH
administration. So, ARC NPY is stimulatory effector on
somatostatin and inhibitory effector on GHRH. Therefore, GH
action of these cells might be involved in food intake activity
in the GH/IGF-I axis affecting food utilization. Recently, NPY
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has been considered as a mediator of the effects of GHSs,
and leptin action.
 Leptin.  Leptin is newly discovered hormone product
of obese gene (ob), secreted by adipocytes that regulate
food intake and energy expenditure. Leptin has recently
been shown to play a stimulatory role on GH secretion by
mediating NPY in the hypothalamic area. Alternatively,
leptin and NPY could act through parallel pathway to
change GH release with NPY, overcoming the stimulatory
effect exerted by leptin on plasma GH level. One of the
leptin receptor, ob-Rb is responsible for the leptin
signaling in the brain and expressed in the hypothalamic
area: median eminence (ME), arcuate nucleus (ARC),
ventromedial nucleus (VMN), and dorsomedial nucleus
(DMN). The main physiological role of leptin is to
increase energy expenditure and decrease in food intake
after signal increasing adiposity to the brain. Also, a study
of leptin action on the reproductive system demonstrates
that leptin stimulates the reproductive endocrine system
and suggests that leptin may serve as a permissive signal
to the reproductive system of normal animals. Although
the outline of the hypothalamic system for regulation of
feeding is now more clear, it is still needed to be
investigated to define the mechanisms of neural
regulation of feeding.
Ghrelin.   Ghrelin is the newest player in the
endogenous regulation of GH secretion. Ghrelin, a novel
28 amino acid peptide has recently been purified from rat
stomach and subsequently cloned in rat and human. An
important physiological role of ghrelin is the endogenous
ligand for the GHS-R to induce GH release from pituitary
somatotrophs. Ghrelin has been detected in the
hypothalamic ARC and in the stomach by using
immunocytochemical detection method. This
hypothalamic ghrelin has important physiological roles in
GH secretion and energy balance. In accordance with
synthetic GHSs action, a recent study demonstrated that
intracerebroventricular (i.c.v.) and peripheral (i.p.)
administration of ghrelin induce increase in plasma GH
concentration and this ghrelin-induced GH secretion is
also directly opposed by somatostatin action involving
mediation through GHRH. An animal study confirmed
ghrelin is a regulator of energy balance.  The data showed
that exogenous ghrelin induces adiposity in rodents by
stimulating increase in food intake and a reduction in fat
utilization based on the hypothalamic signaling.
Adipogenic and orexogenic effects of ghrelin are
dissociated from its GH secretion effects and  rather are
associated with a specific central mechanism of neurons
mediated by leptin whose regulation and biological effect
are opposed to those of ghrelin. The further understanding
of central network and function of ghrelin will enlighten
the general frame for hypothalamic machinery in
metabolism regulation.
